Daily Stock List
Cream Minerals Ltd. (CMA.V)
We are highlighting Cream Minerals Ltd. (CMA.V), here at the QualityStocks Daily Newsletter.
Cream Minerals Ltd. is a precious metals exploration company that lists on the TSX Venture Exchange. The Company has a portfolio of five solely owned highly prospective properties, four in Canada and one in Mexico. Their objective is to acquire low risk high reward silver and gold properties and develop them to an advanced stage to maximize shareholder value. Cream Minerals is based in Vancouver, British Columbia.
Currently, the Company's focus is the Nuevo Milenio Silver-Gold Project, Nayarit State, Mexico. The 100 percent owned Nuevo Milenio silver-gold project encompasses 2,560 Hectares (Ha). In addition, the Company has acquired an option to earn a 100 percent interest in the Wine and Wine 1 minerals claims, located approximately 60 kilometers southeast of Flin Flon, Manitoba. The Wine and Wine 1 claims cover an east west trending mafic intrusion (1,700 m X 700 m) that has known copper, nickel, platinum, palladium and gold mineralization spatially related to the intrusion and its contact with the surrounding country rocks.
In addition, Cream Minerals has their Goldsmith Gold Property in British Columbia. The Goldsmith Property is west of Poplar Creek on Highway 31, 66 kilometers north of Kaslo. The Goldsmith Property contains several historic, small, high-grade gold workings (Lucky Jack, Bullock, Swede, Goldsmith, Gold Park, and others) throughout a 3-kilometer long belt of altered volcanic and sedimentary host rocks.
The Company also has their Kaslo Silver Property in British Columbia. The 100 percent owned 4,000-hectare Kaslo Silver Property is located 12 kilometers west of the town of Kaslo. The Kaslo Silver Property encompasses nine former high-grade silver-lead-zinc mines located in southeastern British Columbia.
Furthermore, Cream Minerals has their Blueberry Property in Manitoba. The Blueberry Lake project is contained within Manitoba's prolific Flin Flon-Snow Lake Volcanogenic Massive Sulphide Belt. The Blueberry Lake property is close to the eastern edge of the Manitoba portion of the Flin Flon volcanic belt within a segment of volcanic rocks that stretches from the Manitoba-Saskatchewan border to the Athapapuskow Lake and northeast to Naosap Lake.
Cream Minerals Ltd. (CMA.V), closed Tuesday's trading session at $0.05, up 11.11%, on 90,000 volume. The stock's 52-week low/high is $0.04/$0.29.
Applied Minerals, Inc. (AMNL)
Real Pennies reported earlier on Applied Minerals, Inc. (AMNL), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Applied Minerals, Inc. is the leading producer of Halloysite Clay solutions from their wholly owned Dragon Mine property in Utah. Halloysite is aluminosilicate clay that forms naturally occurring nanotubes. Applied Minerals markets their portfolio of halloysite clay solutions under the Dragonite trademark. Founded in 1924, the Company has their headquarters in New York City.
Applied Minerals also has investments in the characterization of the Dragon iron ore resource, marketed for use in pigments and technical applications, such as smoke suppression and remediation of arsenic and metal contamination. In addition, they hold a broad portfolio of intellectual property surrounding the technology related to their material.
The Company serves the traditional halloysite markets for use in technical ceramics and catalytic applications. Moreover, the Company has developed niche applications that benefit from the tubular morphology of their halloysite. These applications include carriers of active ingredients in paints, coatings and building materials, environmental remediation, agricultural applications, and high-performance additives and fillers for plastic composites.
Applied Minerals holds a 100 percent interest in the Dragon Mine, a halloysite clay property covering an area of approximately 230 acres located in the Tintic District of Utah. The Dragon Mine is the only known measured resource of Halloysite Clay in the western hemisphere significant enough for large-scale commercial production. The Dragon Mine also contains an iron resource consisting of Goethite, Hematite, as well as an amorphous iron phase identified as Ferrihydrite.
Under the Dragonite trademark, Applied Minerals' products include Dragonite™, Dragonite-XR™, Dragonite-HP™, Dragonite-PureWhite™, and Dragonite-IO™. Dragonite™ is a versatile Halloysite product grade with a broad spectrum of applications. These include controlled release, environmental remediation, agriculture, paints and coatings, and catalysts.
Dragonite-XR™ is advanced reinforcing filler. This product features excellent retention of impact resistance, elongation to break, control over CTE and warpage, and lack of abrasiveness. Dragonite-HP™ is a high performance additive for engineering thermoplastics. This product grade offers a drop-in solution for customers who require premier properties without the density penalty associated with traditional fillers.
Dragonite-PureWhite™ is the highest purity Dragonite™ product. It meets the strict specifications of the cosmetics industry. Dragonite-IO™ is a high-grade iron oxide product line from the Dragon Mine. Products include Goethite and Hematite grades for use in pigments and technical applications including smoke suppression and remediation of arsenic and metal contamination.
Applied Minerals, Inc. (AMNL), closed Tuesday at $1.66, up 10.67%, on 417,423 volume with 247 trades. The average volume for the last 60 days is 100,562 and the stock's 52-week low/high is $0.999/$1.94.
Uni Core Holdings Corp. (UCHC)
Actual Gains, Bullseyestox.com, AddictivePennyStocks, PennyStockRumors.net, OTCPicks, Penny Stock Rumble, We Beat Wallstreet, PennyTrader Publisher, and WiseAlerts reported earlier on Uni Core Holdings Corp. (UCHC), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Hong Kong, Uni Core Holdings Corp., via their subsidiaries, develops, manufactures and distributes environmentally friendly paper and agricultural products based upon their proprietary technology and supply chains. Their management team and structure address significant problems with investing and growing companies in China. Founded in 1998, Uni Core's shares trade on the OTC Markets: OTCQB.
APT Paper Group is a wholly owned subsidiary of Uni Core Holdings. APT has their headquarters in Shenzhen, Guangdong, China. They established in November of 1993 and in June 2010 Uni Core acquired 100 percent of APT. APT is one of the leaders of the modern environmentally friendly packing and honeycomb paper products industry in China. This is based upon proprietary technology, production, marketing and global supply chains.
APT's products are constructed from recycled materials and they are recyclable. This subsidiary's products include honeycomb paper pallets, honeycomb paper panels, honeycomb paper cartons, honeycomb paper coffins, honeycomb paper cushions, paper slip-sheets, paper corner protectors, as well as corrugated paper products. APT holds patents internationally on several of their products.
Uni Core Holdings owns 51 percent of Shaanxi Prosperous Agriculture (Prosperous Agriculture). Prosperous Agriculture has their headquarters in Xi'an, Shaanxi Province, China. They manufacture and distribute agricultural brands. Furthermore, they established a national agricultural resources chain direct sales platform. They did this through the opening and acquiring of agricultural resources direct sales outlets and dealers, and by working with well-known manufacturers of agricultural products. Prosperous Agriculture integrated more than 2,000 agricultural resources.
Yesterday, Uni Core Holdings reported that Prosperous Agriculture participated in the China Phosphate Fertilizer and Compound Fertilizer Conference jointly with Luxi Chemical Co. Ltd. on November 9, 2012. Prosperous Agriculture and Luxi Chemical jointly launched "Luxi Shou Er", a new fertilizer compound containing Phyllite energy substance.
The "Luxi Shou Er" compound fertilizer is a product jointly developed by Prosperous Agriculture, Luxi Chemical, JEWON of South Korea, and RDS Solution of Japan. It is exclusively distributed by Prosperous Agriculture nationally.
Uni Core Holdings Corp. (UCHC), closed today at $0.0002, even for the day, on 53,625,749 volume with 13 trades. The average volume for the last 60 days is 59,235,582 and the stock's 52-week low/high is $0.0001/$0.09.
Aura Systems, Inc. (AUSI)
SmarTrend Newsletters reported recently on Aura Systems, Inc. (AUSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Aura Systems, Inc. specializes in axial flux induction machine applications for mobile power generation and electric motors. They design, assemble and sell the AuraGen/VIPER. The AuraGen/Viper is the Company's patented, integrated, mobile power generator and power management system that installs in a motor vehicle and delivers, on-location, both AC and DC electricity for any end user. Aura Systems has their corporate headquarters in El Segundo, California.
The Company's products are categorized either under the AuraGen/Viper or under the Refrigeration classifications. The AuraGen is a new class of axially symmetric induction machines patented by the Company. Induction machines make up 90 percent of all electrical rotating machinery in industry - all consisting of a rotor(s) and a stator(s). As a motor, the AuraGen produces substantially higher torque per unit volume and as a generator, significantly more power per unit volume.
The Vehicle Integrated Primary Electrical Resource "VIPER" is the name given by the military to the AuraGen mobile power system. The VIPER is a ruggedized version of the AuraGen axial flux induction generator. The design of it is to operate under extreme conditions. The VIPER is used in fields such as Homeland Security and the Coast Guard.
Refrigeration systems that the AuraGen powers are an environmentally friendly, no emissions refrigeration system. These systems are for fresh or frozen applications for 14'-24' straight delivery trucks.
Yesterday, Aura Systems announced that their AuraGen/VIPER was selected for a program that would require up to 5,000 systems valued at approximately $150,000,000.00 to be delivered over a seven-year period. The new order is for 5,000 stand-alone diesel generators using the VIPER power solution. In the past most of the Company's military orders were for vehicle integrated solutions.
Mr. Melvin Gagerman Aura Systems' Chief Executive Officer said, "The VIPER mobile power solution is now integrated into numerous military programs for both land and sea applications. We now have our VIPER mobile power solutions in 20 countries and expect more countries to use the VIPER in the near future. It is important to understand that all of our backlog is for major global users and these users are now integrating our systems into their working environment for long term applications."
Aura Systems, Inc. (AUSI), closed Tuesday's trading session at $0.48, up 2.13%, on 10,299 volume with 7 trades. The average volume for the last 60 days is 35,030 and the stock's 52-week low/high is $0.21/$0.77.
Crocodile Gold Corp. (CROCF)
Streetwise Reports reported previously on Crocodile Gold Corp. (CROCF), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Crocodile Gold engages in the acquisition, exploration, development, and operation of gold properties. The Company has operating gold mines in the Northern Territory of Australia and in the State of Victoria with a land package of more than 3,900 square kilometers. Currently, Crocodile Gold is mining at the Fosterville and Stawell mines in the State of Victoria. Crocodile Gold lists on the OTC Markets: OTCQX International. The Company is based in Toronto, Ontario.
In the Northern Territory, Crocodile Gold continues to develop their Cosmo underground mine. With production starting at the Cosmo Mine, the Company's main exploration focus is at the Union Reefs and Maud Creek project areas. In addition, they are continuing with the permitting processes for the International open pit mine. The Northern Territory ore production undergoes processing at the Union Reefs Mill. This mill has a capacity of 2.4 million tonnes annually.
At the Company's Northern Territory properties, they have 3.175 million ounces of NI 43-101 reported Measured and Indicated mineral resources (51.85 million tonnes at an average grade of 1.9 g/t gold) and 2.14 million ounces of Inferred mineral resources (36.35 million tonnes at an average grade of 1.8 g/t gold).
These resources are inclusive of mineral reserves. At the State of Victoria properties, Crocodile Gold has an additional 1.216 million ounces of NI 43-101 reported Measured and Indicated mineral resources (15.26 million tonnes at an average grade of 2.48 g/t gold) and 0.622 million ounces of Inferred mineral resources (6.00 million tonnes at an average grade of 3.22 g/t gold). These are exclusive of mineral reserves, which total 0.472 million ounces (3.38 million tonnes at an average grade of 4.34 g/t gold).
Last week, Crocodile Gold released their financial and operating results for the three months ended September 30, 2012. They had revenues of $78,721,463 on third quarter gold sales of 47,121 ounces. This represents a sequential increase of 32 percent over the second quarter reflecting the realization of the integration of the Fosterville and Stawell Gold Mines and a strong gold price environment.
The mine operating earnings in the third quarter were $7,028,408 compared to $5,949,787 for the three months ended June 30, 2012, an increase of 18 percent. The cash cost per ounce of gold sold in the third quarter was $1,176 per ounce compared to $1,167 per ounce in the second quarter.
Net loss for the quarter ended September 30 was $55,998,228 or $0.14 per share. This is in comparison to a net loss of $7,225,054 or $0.02 per share for the quarter ended June 30, 2012. Their net loss for the quarter was impacted by significant non-cash charges. This includes a loss from the revaluation of derivative liabilities of $49,938,647 and a loss from the change in fair value of contingent consideration of $4,335,178, both because of the significantly higher gold price forward curve at quarter-end compared to June 30, 2012.
Crocodile Gold Corp. (CROCF), closed Tuesday at $0.3687, up 1.85%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 24,863 and the stock's 52-week low/high is $0.288/$0.6066.
Passport Potash, Inc. (PPRTF)
StreetWise Reports, StockHouse, Jason Bond, and PennyStockLive reported earlier on Passport Potash, Inc. (PPRTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQX International, Passport Potash, Inc. engages in the exploration and development of advanced potash properties. The Company's primary focus is on a previously explored potash property in Arizona. Passport Potash has acquired a strategic position in the Holbrook Basin with land holdings encompassing more than 121,000 acres. The Company is based in Vancouver, British Columbia.
Passport Potash has also entered into a joint exploration agreement with the Hopi Indian Tribe to work toward developing more than 13,000 acres of contiguous privately held Hopi land. The Holbrook Basin project is seven miles east of Holbrook, Arizona. The project sits atop a large salt basin known as the Holbrook Salt Basin.
Passport is utilizing the historic records combined with their own drilling program and seismic testing to substantiate the potash grade and quantity on their properties. Thirty new holes have been drilled on the Company's holdings since 2009, as well as 100 line miles of seismic survey.
Passport earlier announced the completion of the initial NI 43-101 compliant mineral resource estimate by ERCOSPLAN Ingenieurgesellschaft Geotechnik und Bergbau mbH (ERCOSPLAN) for the Company's Holbrook Basin property in Northern Arizona. Headquartered in Erfurt, Germany, ERCOSPLAN is a consulting and engineering firm, specializing in the potash and salt industry.
This initial resource estimate consists of 125.6 million tonnes of indicated mineralized material with an average KCl grade of 14.29 percent (equivalent to an Indicated Resource of 17.96 million tonnes of KCl) and 587.8 million tonnes of inferred mineralized material with an average KCl grade of 12.20 percent (equivalent to an Inferred Resource of 71.71 million tonnes of KCl). At present, the estimated resources cover only approximately 40 percent of Passport Potash's current holdings.
Last week, Passport Potash announced that they arranged a non-brokered fully subscribed private placement for 69,444,444 Units at a price of $0.18. Each Unit consists of one common share and one-half of one share purchase warrant. Each warrant will entitle the holder to purchase an additional common share at a price of $0.25 for a period of five years. The proceeds from the private placement will be used for property payments, general working capital and the exploration program of the Company.
Passport Potash, Inc. (PPRTF), closed Tuesday's trading at $0.22, up 4.76%, on 9,200 volume with 5 trades. The average volume for the last 60 days is 131,711 and the stock's 52-week low/high is $0.16/$0.40.
LianDi Clean Technology, Inc. (LNDT)
Dynamic Wealth Report and FeedBlitz reported earlier on LianDi Clean Technology, Inc. (LNDT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
LianDi Clean Technology, Inc. is a holding company whose shares trade on the OTC Bulletin Board. By way of their subsidiaries, the Company provides downstream flow equipment and engineering services to petroleum and petrochemical industries in China. LianDi Clean Technology established in 2004. The Company has their corporate headquarters in Beijing, The People's Republic of China (PRC).
LianDi primarily engages in distributing clean technology for refineries (unheading units for the delayed coking process), distributing a broad array of petroleum and petrochemical valves and equipment, providing systems integration, developing and marketing optimization software and providing related technical and engineering services to large domestic Chinese petroleum and petrochemical companies and other energy companies.
China LianDi Clean Technology Engineering Ltd. is the holding company of the other subsidiaries. The Hua Shen Trading (International) Ltd. subsidiary delivers industrial valves and other equipment. They also offer related integration and technical services.
Petrochemical Engineering Ltd. also delivers industrial valves and other equipment. They also offer related integration and technical services. In addition, this subsidiary has investment holdings. LianDi's Bright Flow Control Ltd. subsidiary also delivers industrial valves and other equipment and offers related integration and technical services.
Beijing JianXin Petrochemical Engineering Ltd. also delivers and offers the aforementioned, and develops and markets optimization software, and provides delayed coking solutions for petrochemical, petroleum and other energy companies. Moreover, LianDi's Hongteng Technology Ltd. subsidiary is an investment holding company.
The Company's Beijing Hongteng Weitong Technology Co., Ltd. subsidiary delivers industrial valves and other equipment and offers related integration and technical services. This subsidiary develops and markets software, and provides other technical consultancy services for petrochemical, petroleum and other energy companies.
In addition, LianDi Clean Technology also engages in the manufacturing and selling of industrial chemicals. This is operated via their equity method affiliate, Anhui Jucheng Fine Chemicals Co., Ltd. (Anhui Jucheng). They engage in the development, manufacture, and sale of organic and inorganic chemical products, and high polymer fine chemical products. They also provide chemical professional services.
LianDi Clean Technology, Inc. (LNDT), closed Tuesday's session at $0.84, up 5.00%, on 18,500 volume with 3 trades. The average volume for the last 60 days is 1,817 and the stock's 52-week low/high is $0.77/$2.15.
Centric Health Corp. (CHH.TO)
Today we are reporting on Centric Health Corp. (CHH.TO), here at the QualityStocks Daily Newsletter.
Listed on the Toronto Stock Exchange, Centric Health Corp. is Canada's leading diversified healthcare services company. The Company has accrued a national platform for delivery of a wide spectrum of services through over 3,600 staff and consultants at close to 1,000 locations. Centric Health has preferred provider contracts with over 50 corporations, government agencies and employers, and over 600 contracts with Long Term Care and Retirement Homes. The Company is based in Toronto, Ontario.
Centric Health's corporate strategy is to build on the strengths of Canada's healthcare system. The Company has large national networks offering innovative healthcare solutions. These include hospital and surgical services; home medical equipment; seniors wellness, and rehabilitation clinics. These also include pharmacy; homecare; medical assessments, and diagnostics.
Centric has completed more than 15 acquisitions over the past two years. Further to their acquisition strategy, the Company is focusing on organic growth initiatives, including cross-selling activities and new service introductions across their business segments. One of the largest and most advanced opportunities is bundled service contracts to long-term care and retirement homes. Centric has recently signed several such contracts and they expect to sign further contracts in the coming quarters.
Additionally, utilization within the Surgical and Medical Centers remains low. This presents a high-margin growth opportunity as operations already are above the break-even point and Centric Health will take advantage of their already fixed asset cost base. The Company has several initiatives to capitalize on this excess capacity. They recently launched the first of many planned surgical Centers of Excellence (COEs) and plan to launch additional COEs in 2013 and beyond. Other initiatives for the Company include increasing retail sales, rolling out orthotics and expanding massage therapy within the Physiotherapy network.
Last week, Centric Health announced financial results for the third quarter ended September 30, 2012. Consolidated revenue for the third quarter of 2012 increased by 60 percent to $107.4 million from $67.1 million for the comparable period of 2011. The increase is primarily due to a number of notable acquisitions, as well as organic growth. Consolidated revenue for the first nine months of 2012 increased by 163 percent to $325.7 million from $123.7 million for the comparable period of 2011.
Centric Health Corp. (CHH.TO), closed Tuesday's trading session at $0.51, down 5.56%, on 385,659 volume. The stock's 52-week low/high is $0.47/$1.89.
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.35, up 40.00%, on 2,155 volume with 2 trades. The stock’s average daily volume over the past 60 days is 9,354, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.
The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.
Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.
Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer Third Quarter Revenue More Than Triples To $555,000
Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles
Lumiere Pavilions Continues Rapid Expansion of ButtKicker® Footprint, Adding Sixth and Seventh Theater Installations of Guitammer's Patented "4D" Technology
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.69, even for the day, on 500 volume with 1 trades. The stock’s average daily volume over the past 60 days is 849, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.011, off by 4.35%, on 2,076,953 volume with 19 trades. The stock’s average daily volume over the past 60 days is 1,548,290, and its 52-week low/high is $0.0013/$0.015.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
VIASPACE, Inc. Announces Engagement of QualityStocks Investor Relations Services
Renewable Giant King Grass is Growing in St. Croix; VIASPACE Now on Facebook and Twitter
VIASPACE CEO Presents at Asian Development Bank Renewable Energy Conference and Meets Customers in Myanmar
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.175, off by 2.78%, on 134,616 volume with 36 trades. The stock’s average daily volume over the past 60 days is 116,996, and its 52-week low/high is $0.174/$0.69.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Latest Product Launch
International Stem Cell Corp Announces Third Quarter 2012 Financial Results
International Stem Cell Corporation to Host Third Quarter 2012 Financial Results Conference Call at 11:00 a.m. ET on Friday, November 9, 2012
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
One of our most popular ways, the QualityStocks Blog, keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. By visiting our blog, investors discover emerging companies that they otherwise would not have heard about.
To view our blog, visit: www.blog.qualitystocks.net
If you would like to subscribe via an RSS reader, here’s our feed URL:http://blog.qualitystocks.net/?feed=rss2
Ohr Pharmaceutical has expanded its Scientific Advisory Board (SAB) with the addition of two prominent ophthalmologists who will join the current panel of retinal ophthalmology experts focused on advancing the company’s Squalamine eye drop program into clinical efficacy trials.
David S. Boyer, M.D. of Retina-Vitreous Associates Medical Group in Los Angeles and Lawrence J. Singerman, M.D. of Retina Associates of Cleveland were appointed to Ohr Pharmaceutical’s SAB to advise the company on its clinical programs, regulatory strategy, and to provide strategic guidance to support the development of Squalamine.
“We are pleased to be working with thought leaders in the retina community of the caliber of Drs. Boyer and Singerman,” Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical stated in the press release. “Their addition to our ophthalmic SAB, together with their past experience in the clinical advancement of numerous FDA approved retinal therapeutics, including Eylea® and Lucentis®, will immensely help the company move the Squalamine eye drop program forward into its first clinical trial, which is expected to be in in the third quarter of 2012.”
Dr. Boyer is a board-certified ophthalmologist and senior partner at Retina-Vitreous Associates Medical Group. Dr. Boyer, who is also a published writer and lecturer, is a clinical professor with the University of Southern California. He has been involved in trials studying age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.
Dr. Singerman is also a board-certified ophthalmologist and published author, and is the founder of Retina Associates of Cleveland, where he and eight other retina specialists see patients throughout Northern Ohio. Dr. Singerman is active in the field of clinical research and has been a principal investigator in more than 75 multicenter clinical trials sponsored by NIH and pharmaceutical companies.
Preclinical testing has demonstrated the Squalamine eye drop formulation as safe to ocular tissues. The formulation achieves in excess of target anti-angiogenic concentrations in the tissues of the back of the eye. In May 2012, the Squalamine eye drop program was granted Fast Track Designation by the U.S. FDA.
For more information, visit www.ohrpharmaceutical.net
NeoStem is a firm engaged in the fast growing cell therapy industry. This industry is expected to have a significant role in the future in the fight against chronic disease. The company’s contract development and manufacturing service business, Progenitor Cell Therapy LLC, supports the development of proprietary cell therapy products.
The company today announced that it has been awarded a two-year grant totaling $1,221,854 from the National Institute of Dental and Craniofacial Research, a division of the National Institute of Health (NIH). The grant was for “Repair of Bone Defects With Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)”. NeoStem has an exclusive worldwide license to VSEL technology.
This peer-reviewed grant will support a Phase II investigation and the first approved NIH clinical study of VSELs. The study, headed by Neostem’s Dennis O. Rodgerson, Ph.D., will be conducted in collaboration with Drs. Russell Taichman and Laurie McCauley of the University of Michigan. Enrollment of the study is expected to begin in 2013.
The study revolves around the evaluation of VSEL stem cells as a potential treatment for periodontitus. This disease affects up to 90% of the world’s population. The most severe form of periodontitus affects between 5% and 15% of the U.S. population. NeoStem’s product candidate is an autologous therapy derived from a patient’s own stem cells. Its aim is the regeneration of bone tissue damaged by severe periodontitus disease.
The market NeoStem’s therapy will be addressing is believed to generate $1.25-$1.5 billion annually. For additional information about NeoStem and VSEL technology, please visit www.neostem.com.
Axxess Unlimited, an emerging data flow management and digital marketing company focused on large market opportunities, recently announced the introduction of its first ignition interlock mobile application, the Axxess Information Reporting (AIR) app. Now available through Apple for the iPhone and iPad, this app will soon be launched on the Android market as well.
Featuring an intuitive interface and up-to-date information, the AIR app includes a breath alcohol calculator (BAC) to prevent those with an interlock from violating their restricted driving privilege, a sales and service locator, the company’s “Connect to Cab” feature, and the previously announced “Refer a Friend” portal, which helps distributors and manufacturers boost their marketing initiatives through incentives. This referral ability is just one of many new ways Axxess is transforming the traditional interlock company from a simple hardware distributor into a data-driven income generator.
“The ‘Refer a Friend’ portal has helped us grow faster than any of our competitors in our market,” stated Laura Cardenas, General Manager of Arizona Monitoring Systems, an interlock distributor. “We have over 30 referring groups that make money by referring clients to us, and that number is virtually unlimited.”
Michael Roth, Chairman and CEO of Axxess, stated, “We are very excited about this first application, not only because it is groundbreaking in the interlock space, but also because it showcases the very best of what we do in terms of application marketing. We see this application as a great example of the kind of apps that can really save clients money and deliver significant returns over the long run.”
For more information on Axxess Unlimited and its patented technology, visit www.axxessunlimited.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
- GreeneStone Healthcare Corp. (GRST) Seeks Amex Listing - New Report Confirms Demand
- International Stem Cell Corp. (ISCO) Lifeline Cell Technology Products to Be Added to Fisher Scientific's Catalogs
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for the Third Quarter of 2012
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- TNI BioTech Inc. (TNIB) and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
- VistaGen Therapeutics, Inc. (VSTA) Completes $3.25 Million Financing and $3.0 Million Debt Restructuring